Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration and European Medicines Agency TARRYTOWN, N.Y., April 07, 2024 -- Regeneron...
Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin...